You can buy or sell IMV and other stocks, options, ETFs, and crypto commission-free!
IMV Inc. Common Shares, also called IMV, is a clinical-stage biopharmaceutical company pioneering a new class of immunotherapy in Oncology. Read More Its proprietary drug delivery platform (DPX) enables the programming of immune cells in vivo. The firm's candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is in clinical evaluation as a monotherapy in advanced ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.
Dartmouth, Nova Scotia
52 Week High
52 Week Low
Financial PostDec 8
Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology Annual Meeting7/9 (77.8%) evaluable subjects exhibited clinical benefit, including three complete responses and two partial responses Reproducible survivin-specific T cell r